Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PDE5A | O76074 | 4/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ACP1 | P24666 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1870772 | 0.73 | L3MBTL1 (0.52) | MEN1KMT2ANPC1LMNAMAPT | |
| SCHEMBL8193283 | 0.73 | CYP3A4 (0.39) | MEN1KMT2ACYP1A2LMNAMAPT | |
| SCHEMBL4754619 | 0.73 | CYP1A2 (0.42) | ABCG2PDE5ACYP1A1CYP1A2CYP1B1 | |
| SCHEMBL4741666 | 0.72 | MAOA (0.43) | MEN1KMT2APDE5ANPC1MAPT | |
| SCHEMBL857662 | 0.71 | LMNA (0.39) | MEN1KMT2ACYP1A2LMNAMAPT | |
| SCHEMBL5251836 | 0.71 | DCPS (0.47) | MEN1KMT2ACYP1A2NPC1LMNA | |
| SCHEMBL8515886 | 0.71 | MAPT (0.36) | ABCG2KMT2ACYP1A1CYP1A2CYP1B1 | |
| SCHEMBL7954324 | 0.71 | CYP11B2 (0.44) | CYP1A2 | |
| SCHEMBL27719232 | 0.71 | RAB9A (0.44) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23069184 | 0.68 | NUDT1 (0.49) | CYP1A2LMNAMAPTRECQLRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653088-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-18 | — | — | US | claimed |
| US-20130245033-A1 | AMIDE COMPOUNDS | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2013-09-19 | — | — | US | claimed |
| US-20090325968-A1 | Compositions Useful as Inhibitors of Protein Kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-31 | — | — | US | claimed |
| US-20040192682-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-09-30 | — | — | US | claimed |
| WO-2004072029-A2 | PYRAZOLOPYRIDAZINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-08-26 | — | — | WO | claimed |
| WO-2024113351-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR MATURING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024113354-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-06-06 | — | — | WO | disclosed |
| US-11518756-B2 | Arylation method | UMICORE AG & CO. KG (DE) | 2022-12-06 | — | — | US | disclosed |
| EP-3383861-B1 | BUCHWALD-HARTWIG ARYLATION METHOD FOR THE PREPARATION OF TERTIARY AMINES | UMICORE AG & CO KG (DE) | 2021-03-17 | — | — | EP | disclosed |
| US-20200031803-A1 | ARYLATION METHOD | UMICORE AG & CO. KG (DE) | 2020-01-30 | — | — | US | disclosed |
| EP-3383861-A2 | ARYLATION METHOD | Umicore AG & Co. KG (DE) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017093427-A2 | ARYLATION METHOD | UMICORE AG & CO. KG (DE) | 2017-06-08 | — | — | WO | disclosed |
| WO-2005087752-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050113378-A1 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | JANSSEN PHARMACEUTICA, N.V. | 2005-05-26 | — | — | US | disclosed |
| US-20040192682-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-09-30 | — | — | US | disclosed |
| WO-2004072029-A2 | PYRAZOLOPYRIDAZINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-08-26 | — | — | WO | disclosed |
| EP-1317452-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002022608-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-03-21 | — | — | WO | disclosed |
| US-6124330-A | A RETINOIC MIMETIC COMPOUND FOR TREATING A WARM-BLOODED ANIMAL SUFFERING FROM A DISEASE BY AN ABNORMAL PROLIFERATION AND/OR ABNORMAL DIFFERENTIATION OF NORMAL, PRENEOPLASTIC OR NEOPLASTIC CELLS | JANSSEN-CILAG S.A. (FR) | 2000-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245033-A1 | AMIDE COMPOUNDS | AR, AVPR2, H1-0 | ABCG2 60/4885MEN1 2383/4885KMT2A 1161/4885 |
| US-20050113378-A1 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | CYP2S1, CYP2D6, CYP2C19 | ABCG2 202/4885MEN1 1061/4885KMT2A 2242/4885 |
| US-20040192682-A1 | Compositions useful as inhibitors of protein kinases | GSK3A, GSK3B, CSNK1A1 | ABCG2 2832/4885MEN1 1266/4885KMT2A 2215/4885 |
| US-20090325968-A1 | Compositions Useful as Inhibitors of Protein Kinases | GSK3A, GSK3B, GSKIP | ABCG2 2527/4885MEN1 1719/4885KMT2A 1927/4885 |
| US-11518756-B2 | Arylation method | AHR, ARNT, CYP2B6 | ABCG2 364/4885MEN1 3371/4885KMT2A 660/4885 |
| US-20200031803-A1 | ARYLATION METHOD | AHR, ARNT, CYP2B6 | ABCG2 364/4885MEN1 3371/4885KMT2A 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.